Harvest Investment Advisors LLC Buys New Holdings in Bristol Myers Squibb Company $BMY

Harvest Investment Advisors LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 36,770 shares of the biopharmaceutical company’s stock, valued at approximately $1,983,000.

Other large investors have also recently bought and sold shares of the company. Kemnay Advisory Services Inc. purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $61,000. Seneca House Advisors purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $213,000. Captrust Financial Advisors boosted its position in Bristol Myers Squibb by 18.4% in the 4th quarter. Captrust Financial Advisors now owns 541,683 shares of the biopharmaceutical company’s stock worth $29,218,000 after purchasing an additional 84,161 shares in the last quarter. &PARTNERS boosted its position in Bristol Myers Squibb by 12.3% in the 4th quarter. &PARTNERS now owns 142,840 shares of the biopharmaceutical company’s stock worth $7,710,000 after purchasing an additional 15,701 shares in the last quarter. Finally, Siemens Fonds Invest GmbH boosted its position in Bristol Myers Squibb by 2.3% in the 4th quarter. Siemens Fonds Invest GmbH now owns 74,658 shares of the biopharmaceutical company’s stock worth $4,047,000 after purchasing an additional 1,674 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Down 0.6%

Shares of NYSE:BMY opened at $55.91 on Wednesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a market capitalization of $114.18 billion, a price-to-earnings ratio of 15.71, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The business’s 50 day moving average price is $57.59 and its 200-day moving average price is $57.03.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Wall Street Zen lowered Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.